Novo Nordisk abruptly ended its partnership with Hims & Hers after the Danish drugmaker accused the telehealth company of illegally selling cheaper copycats of Novo Nordisk’s weight-loss drug and engaging in deceptive marketing.

Hims & Hers Health Inc. (NYSE: HIMS) shares are trading higher Thursday. The stock appears to be bouncing back a bit after selling off to start the week. Here's a look at what you need to know.

The loss of its ability to sell Wegovy is a significant hit to Hims & Hers' business. The massive drop today in its stock reflects this, but even after falling more than 30%, the stock is still too expensive for my taste.